Credits Available: 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC

Description: Despite significant advancements in treatment, multiple myeloma remains an incurable disease, and nearly all patients experience relapse, often requiring increasingly complex therapeutic strategies.

With the rapid expansion of treatment options, particularly novel targeted therapies such as GPRC5D-directed approaches, the landscape of relapsed/refractory multiple myeloma (RRMM) management is evolving at an unprecedented pace. While these agents offer deep and durable remissions, their integration into clinical practice presents challenges in sequencing, toxicity management, and multidisciplinary coordination.

This educational initiative is designed to empower clinicians with the latest insights on GPRC5D-targeted therapies, facilitate the exchange of real-world clinical experience, and provide actionable strategies for optimizing patient outcomes. Through interactive discussions and expert-led guidance, participants will gain practical knowledge to navigate the complexities of RRMM treatment while fostering collaborative networks to enhance long-term patient care.

Join us to stay at the forefront of innovation in multiple myeloma management and elevate your clinical practice.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Nurse, Physician Associate/Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Julia Fadul

Moffitt Cancer Center
Clinical Pharmacy Specialist, Malignant Hematology

I am a malignant hematology clinical pharmacy specialist at Moffitt Cancer Center in Tampa Florida. My practice areas include acute leukemias, multiple myeloma, and lymphomas.